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Identification of Novel Small-Molecule Inhibitors
of Severe Acute Respiratory Syndrome-Associated
Coronavirus by Chemical Genetics
the virus [9], highlighting the rapid responses of the
scientific community to this previously unknown global
pathogen.
Advancements in synthetic organic chemistry, molec-
ular biology, and informatics have made possible the
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Recent findings demonstrate that the first step in
SARS-CoV infection is mediated by S protein associa-The severe acute respiratory syndrome-associated
tion with ACE2 [9]. After being internalized into the targetcoronavirus (SARS-CoV) infected more than 8,000
cells, SARS-CoV undergoes a very rapid replication cy-people across 29 countries and caused more than 900
cle through a series of concerted transcriptional, transla-fatalities. Based on the concept of chemical genetics,
tional, posttranslational, and proteolytic processingwe screened 50,240 structurally diverse small mole-
events, leading to maturation and release of infectivecules from which we identified 104 compounds with
viral particles into the culture supernatant [17–19]. Weanti-SARS-CoV activity. Of these 104 compounds, 2
speculated that the various biological pathways in-target the SARS-CoV main protease (Mpro), 7 target
volved in viral pathogenesis could be perturbed by smallhelicase (Hel), and 18 target spike (S) protein-angio-
molecules using chemical genetic approaches. To ex-tensin-converting enzyme 2 (ACE2)-mediated viral en-
amine the feasibility of employing chemical genetictry. The EC50 of the majority of the 104 compounds
approaches in SARS-CoV research, we acquired adetermined by SARS-CoV plaque reduction assay
chemical library (ChemBridge Corporation) of 50,240were found to be at low micromolar range. Three se-
structurally diverse small-molecule compounds thatlected compounds, MP576, HE602, and VE607, vali-
vary in functional groups and charges. As the SARS-dated to be inhibitors of SARS-CoV Mpro, Hel, and viral
CoV replicates effectively in Vero cells (African greenentry, respectively, exhibited potent antiviral activity
monkey kidney cell line) and full cytopathic effects (CPE)(EC50  10 M) and comparable inhibitory activities in
of the infected cells can be observed within 96 hr postin-target-specific in vitro assays.
fection, Vero cell CPE was used as a phenotypic indica-
tor of successful viral infection in a cell-based assay to
Introduction screen for small-molecule compounds that perturb the
infectivity of the virus. The employment of high-throughput
The severe acute respiratory syndrome-associated co- screening (HTS) technologies to generate a collection
ronavirus (SARS-CoV) recently emerged as the caus- of structurally diverse small-molecule compounds per-
ative agent of an endemic atypical pneumonia. Within turbing the pathogenesis of the SARS-CoV will lay down
a year, SARS-CoV infected more than 8,000 people the foundation to dissecting the molecular basis of viral
across 29 countries and cost more than 900 human lives infections using chemical genetics.
[1]. Lack of knowledge of the novel coronavirus SARS-
CoV and the absence of efficacious therapeutic agents
were the main reasons for the failure to manage the Results and Discussion
outbreak of SARS effectively. After the causative agent
of the devastating disease was identified by us and Phenotype-Based HTS
others [2–4], the genome of SARS-CoV was decoded In a primary screening (at 20 g/ml of each compound),
rapidly by several groups [5–7]. Subsequently, reverse we identified 1003 “hits” (a hit rate of 2%) that protected
genetics with SARS-CoV cDNA was accomplished [8], Vero cells from SARS-CoV-induced CPE. When the hits
and ACE2 was identified as a functional receptor for were rearrayed and the concentration of selected com-
pounds was lowered to 10 g/ml for secondary screen-
ing, 104 compounds retained consistent protective ef-*Correspondence: rytkao@hkucc.hku.hk
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Figure 1. Isolation of Biologically Active Small-Molecule Inhibitors of SARS-CoV in a Phenotype-Based Screen
A schematic illustration of major processes involved in the phenotype-based screen is shown. Enlarged images of Vero cells from a typical
384-well tissue culture plate used in screening are also included to indicate the criteria for hit selection. Only those compounds that fully
protected the Vero cells from SARS-CoV-induced CPE were selected as hits.
fects against SARS-CoV-induced CPE in Vero cells of the viral Mpro. The purified SARS-CoV Mpro cleaved
efficiently and specifically a synthetic peptide with the(Figure 1). Further evaluation by quantitative plaque re-
duction assays demonstrated that the EC50 (median ef- sequence H2N-TSAVLQ↓SGFRKW-COOH mimicking the
putative autolytic cleavage site (the cleavage site is indi-fective concentration) of the selected compounds were
below 10 g/ml, with 78 compounds having an EC50 cated with a ↓) of the N-terminal part of Mpro [22]. Screen-
ing of the 104 compounds at a concentration of 20g/mlbelow 2 g/ml. For subsequent studies, the concentra-
tions of selected compounds were converted to molar identified two candidates as potential inhibitors of the
SARS-CoV Mpro. One of the compounds (designatedunits for more precise comparison of their biological
activities. The TC50 (median toxic concentration) of se- MP576) displayed potent inhibitory activity with an IC50
(median inhibitory concentration) of 2.5 M (Figure 2A)lected compounds was determined to be 50 M by
MTT (3-[4,5-dimethylth-iazol-2-yl]-2,5-diphenyltetrazol- and an EC50 of 7 M in the Vero cell-based SARS-CoV
plaque reduction assay (Figure 2B). Furthermore, MP576ium bromide) assay. To test our hypothesis that the
104 selected compounds represent diverse molecular can be docked favorably into the active site of SARS-
CoV Mpro (Figure 2C), consistent with the in vitro cleavageblockers of various biological pathways crucial for
SARS-CoV infectivity, we screened for molecules tar- data indicating that MP576 is a novel nonpeptide inhibi-
tor of SARS-CoV Mpro. Since SARS-CoV Mpro shares ageting viral entry, transcription, and proteolytic pro-
cessing, the three major processes essential for suc- similar structural fold with serine proteases [21, 23], we
tested the inhibitory activity of MP576 on human neutro-cessful viral replication in the host.
phil elastase (HNE). Using azocasein as the substrate,
we demonstrated that 100 M of MP576 failed to inhibitCompounds Targeting SARS-CoV Mpro
SARS-CoV Mpro is believed to play a major role in proteo- the proteolytic activity of HNE (Figure 2D), suggesting
that MP576 is not a general protease inhibitor.lytic processing of the viral polyproteins and is regarded
as a prime target for anti-SARS-CoV drug development
[20, 21]. The recently available crystal structure of the Compounds Targeting SARS-CoV Hel
To identify compounds that interfere with viral compo-SARS-CoV Mpro makes it a suitable target for structure-
based rational drug design [22]. We cloned the SARS- nents essential for transcription and replication, we se-
lected the SARS-CoV Hel, which we had previouslyCoV Mpro in an E. coli expression system and obtained
purified enzyme to examine if any of the 104 selected cloned and characterized [24], for our assay system. It
was demonstrated that the SARS-CoV NTPase/helicasecompounds targets this vital component of the virus.
High-performance liquid chromatography (HPLC)-based had an unstimulated ATPase activity that could be stim-
ulated by the addition of polynucleotides, in particularassays were used to monitor the in vitro cleavage activity
Novel Small-Molecule Inhibitors of SARS-CoV
1295
Figure 3. HE602 Targets SARS-CoV Hel
(A) HE602 inhibited polynucleotide-stimulated ATPase activity ofFigure 2. MP576 Targets SARS-CoV Mpro
SARS-CoV Hel.(A) MP576 inhibited in vitro cleavage activity of SARS-CoV Mpro with
(B) HE602 (200 M) did not inhibit significantly the nonstimulatedan IC50 of 2.5 M. Synthetic peptide H2N-TSAVLQSGFRKW-COOH
ATPase activity.was used as the substrate in the assay.
(C) Inhibition of SARS-CoV Hel helicase activity by HE602 observed(B) MP576 inhibited SARS-CoV plaque formation with an EC50 of
by polyacrylamide electrophoresis of labeled duplex and single-7 M.
stranded DNA. The positions of the 32P-labeled DNA partial duplex(C) MP576 is predicted to occupy the active site of SARS-CoV Mpro
and released single strand are indicated to the left of the polyacryl-(left) and hydrogen bonds with Cys145 N and His41 N2 (right). The
amide gel (the star indicates the position of the 32P label).active site of SARS-CoV Mpro is shown as a surface model (left) and
(D) HE602 inhibited SARS-CoV plaque formation with an EC50 ofthe backbone trace (light blue) of SARS-CoV is shown, along with
6 M.the side chains of residues crucial for substrate binding and cataly-
(E) Chemical structure of HE602 (3-Benzyloxy-N-(4-chloro-3-oxa-sis (right). MP576 carbons are shown in green. Predicted hydrogen
zolo[4,5-b]pyridine-2-yl-phenyl)benzamide).bonds are shown as dashed lines.
(D) MP576 (100 M) did not inhibit human neutrophil elastase (HNE).
Azocasein was used as the substrate in the assay.
at a concentration of 20 g/ml. Seven compounds ex-(E) Chemical structure of MP576 (3-quinolinecarboxylic acid,
1,4,5,6,7,8-hexahydro-2-methyl-4-(2-nitrophenyl)-5-oxo-, 2-pheny- hibited inhibitory activity. One of the compounds (desig-
lethyl ester). nated HE602) exhibited substantial inhibitory activity at
2 g/ml. HE602 was found to strongly inhibit the poly-
nucleotide-stimulated ATPase activity of SARS-CoV Hel
with an IC50 of 6.9M (Figure 3A), but barely inhibited thedT24. As the functional conformation of the helicase is
likely to be the nucleic acid-bound state, we initially unstimulated ATPase activity even at a concentration of
200 M (Figure 3B). In the helicase assay, a duplexscreened the 104 active compounds against the poly-
nucleotide-stimulated ATPase activity of SARS-CoV Hel DNA was prepared incorporating a 5 overhang that is
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required for SARS-CoV helicase activity. The shorter
strand of the duplex DNA incorporated a 32P label so that
differential migration of the duplex or single-stranded
oligonucleotide could be easily observed following poly-
acrylamide gel electrophoresis. It can be clearly seen
that both 200 and 20 M concentrations of HE602 inhib-
ited the helicase activity of the SARS-CoV Hel, while 2
and 0.2 M concentrations did not inhibit the helicase
activity (Figure 3C). It was only possible to perform a
qualitative assay with this system, but these results are
fully consistent with the IC50 value that we measured
using our quantitative ATPase assay. Furthermore,
HE602 inhibited the viral plaque formation in Vero cell
with an EC50 of 6 M (Figure 3D). The effective inhibition
of only the stimulated ATPase activity together with its
ability to inhibit helicase activity indicates that HE602
has distinct parallels with the pharmacological profiles
of inhibitors targeted against the herpes simplex virus
(HSV) helicase-primase protein [23, 25].
Compounds Targeting S Protein-ACE2-Mediated
Viral Entry
We used a SARS-CoV pseudotype virus assay to identify
compounds that block S protein-ACE2-mediated cellu-
lar entry of the SARS-CoV. Briefly, 293T cells expressing
ACE2 [9] were infected with SARS-CoV pseudovirus car-
rying the HIV-1 backbone and a luciferase reporter gene.
The viral entry level was quantified by measuring lucifer-
ase activity at 72 hr postinfection. Of the 104 com-
pounds, 18 inhibited the entry of pseudovirus into the
engineered 293T cells. One compound (designated
VE607) inhibited pseudovirus entry with an EC50 of 3 M
(Figure 4A) and inhibited SARS-CoV plaque formation
with an EC50 of 1.6 M (Figure 4B). The viral entry-
blocking property of VE607 was confirmed by using
modified plaque reduction assay that indicates if the
compound is involved in interfering with the viral entry
process; by excluding the inhibitor in the early stage of
the infection when viral entry (0–2 hr postinfection) is
Figure 4. VE607 Blocks S Protein-ACE2-Mediated SARS-CoV Entry
crucial, we demonstrated that the protective effects of
(A) VE607 blocked SARS-CoV S protein pseudotype HIV-1 virus
VE607 against viral plaque formation were greatly re- infection of 293T cells expressing ACE2 with an EC50 of 3 M.
duced (Figure 4C). The viral entry-blocking activity of (B) VE607 inhibited SARS-CoV plaque formation with an EC50 of
VE607 is SARS-CoV specific, as it did not protect Vero 1.6 M.
(C) VE607 (10 M) became ineffective when excluded from thecells from poliovirus plaque formation (Figure 4D).
plaque reduction assay at stage crucial for viral entry (0–2 hr postin-
fection).
Implications and Prospects (D) VE607 (50 M) did not inhibit poliovirus plaque formation.
(E) Chemical structure of VE607 (1-[3-(2-Hydroxyl-3-piperidin-1-yl-We set out to examine the feasibility of establishing
propoxy)-phenoxy]-3-piperidin-1-ylpropan-2-ol).a HTS-based chemical genetic platform to dissect the
molecular mechanisms of SARS-CoV pathogenesis. We
first used forward chemical genetics to isolate a group
of small-molecule compounds perturbing the pathoge- and proteolytic processing of viral polyproteins) specu-
lated to be crucial for SARS-CoV infection were chosennicity of SARS-CoV in Vero cells from a diverse chemical
library. After screening 50,240 compounds, 104 fulfilled as testing candidates. By selecting without bias these
important molecular targets/pathways and subsequentthe criteria of being protective against SARS-CoV infec-
tion in cell culture without apparent cytotoxicity. The successful identification of their molecular blockers
from the 104 compounds obtained by cell-based HTS,structures of the active compounds varied (unpublished
data), suggesting that this collection of small molecules we can speculate that this reservoir of biologically active
compounds covers most, if not all, biological pathwaysmay modulate different biological pathways involved in
viral propagation. To examine if this selected reservoir crucial to SARS-CoV infection. The specific inhibitory
activities of MP576, HE602, and VE607 in various in vitroof biologically active compounds could be used to probe
essential pathways involved in SARS-CoV infection, assays are summarized in Table 1. Though the inhibitory
roles of MP576, HE602, VE607 and other active com-three pathways (viral entry, transcription/replication,
Novel Small-Molecule Inhibitors of SARS-CoV
1297
Table 1. Specificity of MP576, HE602, and VE607
SARS-CoV Mpro SARS-CoV Hel SARS-CoV Entry Cytotoxicity on
Compound Inhibition (IC50) Inhibition (IC50) Inhibition (EC50) Vero Cells (TC50)
MP576 2.5 M 50 M 50 M 50 M
HE602 50 M 6.9 M 50 M 50 M
VE607 50 M 50 M 3 M 50 M
The highest concentration of compounds used in the assays was 50 M. The specific conditions of each assay employed were stated in
Experimental Procedures.
pounds are indisputable, the precise mode of inhibition Based on the concept of chemical genetics, we have
established a HTS platform to identify small-moleculeof these novel inhibitors is currently under investigation.
In addition, one has to be cautioned that the ultimate compounds that will perturb the pathogenic pathways
of SARS-CoV in Vero cells. After screening 50,240validation of their targets will be the selection of chemi-
cal-resistant viruses and subsequent identification of structurally diverse small-molecule compounds against
SARS-CoV infection in a cellular model, we have identi-genetic mutations conferring the resistant phenotype.
Since CPE in Vero cells was used as a phenotypic fied 104 compounds with potent anti-SARS-CoV activ-
ities. Of the 104 compounds isolated, 2 target theindicator of successful viral infection, one can expect
that the compounds identified in our study could target SARS-CoV main protease (Mpro), 7 target helicase (Hel),
and 18 target spike (S) protein-angiotensin-convertingthe virus, the host, or both. Some compounds may also
have multiple effects; these compounds will be selected enzyme 2 (ACE2)-mediated viral entry. Three selected
compounds, MP576, HE602, and VE607, targetingas hits by our screening system as the sum of the biologi-
cal activities of that compound leads to the protection SARS-CoV Mpro, Hel and viral entry, respectively, ex-
hibited potent antiviral activities in cell-based assaysof Vero cells from SARS-CoV-induced CPE. Screening
the 104 compounds against other common RNA viruses and comparable inhibitory activities in target-specific
in vitro assays. The successful identification of novelindicates that the majority (85%) of the compounds
are SARS-CoV specific while3% have broad spectrum small molecules targeting SARS-CoV Mpro, Hel, and
viral entry, demonstrates that compounds isolatedactivity against all viral candidates tested (R.Y.K. and
K.-Y.Y., unpublished data). From this observation, one from a phenotype-based screen of a large diverse
chemical library provide a reservoir of biologically ac-may speculate that the majority of the compounds se-
lected from a SARS-CoV-based screen will target path- tive small molecules perturbing the pathogenic path-
ways of the virus. Our study validates chemical genet-ways that are unique to SARS-CoV infection, while a
small portion of the compounds may target pathways ics as a rapid and effective approach to tackle
emerging diseases such as SARS and provides a res-common to other RNA viruses. Further studies on this
pool of compounds should lead to better understanding ervoir of novel biologically active small molecules tar-
geting major processes involved in SARS-CoV in-of their mode of actions and the biological processes
involved in viral infections. fection.
While the classical genetic manipulations of the
Experimental ProceduresSARS-CoV are still at pioneering stage [8] and usually
require prior knowledge of the genome, HTS-based
Phenotype-Based HTS
chemical genetics offers an alternative approach to rap- The compounds were assayed at a final concentration of 20 g/ml
idly and systematically perturb the biological pathways in 384-well microtitre plates (Greiner bio-one). Vero cells were
involved in viral pathogenesis. As cell-permeable small seeded at 5 103 cells per well in complete Eagle’s minimal essential
medium (EMEM) (Invitrogen) supplemented with 5% heat-inacti-molecules can rapidly interfere with the functions of their
vated fetal bovine serum (FBS) (Invitrogen), with or without the addi-targets, compounds isolated from our chemical library
tion of chemicals. One hundred TCID50 (50% tissue-culture infectiousshould compose a biologically relevant platform for the
dose) of SARS-CoV strain HKU39849 was added subsequently to
dissection of the dynamic cellular processes involved in each well. Assay plates were incubated at 37C in 5% CO2 for 96
SARS-CoV infection. Furthermore, since no biologically hr. CPE of the infected cells were scored 96 hr postinfection using
active small-molecule inhibitor designed specifically for a Leica DMIL inverted microscope equipped with DC300F digital
imaging system (Leica Microsystems). Experiments were carriedSARS-CoV Mpro, Hel, or S protein-ACE2-mediated entry
out in duplicates. Compounds that exerted full protection (no CPEhas been described thus far, lead optimization of
observed) were selected as hits. The cytotoxicity of selected com-MP576, HE602, and VE607 should yield promising com-
pounds was determined by MTT (3-[4,5-dimethylth-iazol-2-yl]-2,5-
pounds with far superior anti-SARS-CoV activity. diphenyltetrazolium bromide) assay (Roche) according to manufac-
turer’s instructions.
Significance
Virus Plaque Reduction Assay
Twenty-four-well tissue culture plates (TPP, Switzerland) with a con-Viral infection involves complex mechanisms and in-
fluent monolayer of Vero cells (1  105 cells per well) in EMEM withteractions of both the virus and the host. Phenotype-
1% FBS were prepared. One hundred plaque forming units (PFU)based screen in conjunction with high-throughput
of SARS-CoV were added to each well with or without the addition
screening (HTS) technologies provides a biologically of chemicals. After being incubated for 2 hr at 37C with 5% CO2,
relevant platform for the investigation of various im- cell culture media and unbound viral particles were aspirated and
1 ml of overlay (1% low-melting agarose in EMEM with 1% FBS andportant cellular processes involved in viral infection.
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appropriate concentrations of inhibitors) was added to each well (Novagen). ATPase assays were performed using a phosphomolyb-
date-malachite green assay to measure phosphate released as de-immediately. Plates were further incubated for 48 hr under identical
conditions. Cells were fixed by adding 1 ml of 10% formaldehyde. scribed previously [24]. dT24 at a concentration of 200 nM was used
in the polynucleotide stimulated ATPase assay. For the helicaseThe agarose plugs were removed subsequently and cells stained
with 0.5% crystal violet in 70% methanol and the viral plaques assay, 32P-labeled “released” oligo (5-GGTGCAGCCGCAGCGGTG
CTCG-3) was thermally annealed to oligo “5T20” (5-TTTTTTTTTcounted. The poliovirus (type 1) used in the study was a clinical
isolate from a patient in Queen Mary Hospital, Hong Kong. SigmaPlot TTTTTTTTTTTCGAGCACCGCTGCGGCTGCACC-3) in buffer (25
mM HEPES, pH 7.4, 1 mM EDTA, 20 mM NaCl) by heating to 95C8.0 (SPSS) was used for statistical analysis and graph plotting. Ex-
periments were carried out in quadruplicate and repeated twice. for 5 min, followed by cooling to 20C at 0.5C–1C/min. Purified
SARS-CoV Hel protein (0.2 pmol) in 42 l of helicase buffer (25 mMResults are expressed as a percentage of controls in the absence
of inhibitors. The mean value is shown with standard deviation (SD). HEPES, pH 7.4, 10% glycerol, 1 mM DTT, 5 mM magnesium acetate)
Dose-response data are best fit to the logistic equation. was incubated at 20C with 1 l of either DMSO, or inhibitor in
DMSO (to the appropriate final concentration), for 5 min, then
Purification of SARS-CoV Mpro 32P-labeled d5T partial DNA duplex was added (0.2 pmol, 3.9 ng).
and HPLC-Based Cleavage Assay The reaction was initiated by the addition of ATP to 0.2 mM (where
The coding sequence of SARS-CoV Mpro was cloned from SARS- applicable) and was incubated at 20C for 6 min before quenching
CoV strain HKU39849 and inserted into plasmid pET28b (Novagen) with 12 l of SDS-loading buffer (2.5% SDS, 40 mM EDTA, 0.1%
and expressed as a His-tag fusion protein in E. coli BL21 cells xylene cyanol, 0.05% bromophenol blue, 15% w/v Ficoll). 12 l
(Novagen). Culture was induced with 0.5 mM isopropyl--D-thioga- aliquots were immediately resolved on 15% polyacrylamide gels in
lactoside (IPTG) for 4 hr and cell pellet sonicated subsequently. 0.5 TBE (45 mM Tris base, 5 mM EDTA, 45 mM boric acid) at 20C.
After affinity purification by HiTrap Chelating column and cleaved For the positive control, 0.2 pmol of 32P-labeled 5T20 partial DNA
with factor Xa (Amersham Biosciences) to release the N-terminal duplex was denatured by heating to 95C for 5 min, then flash cooling
His tag, the authentic SARS-CoV Mpro was further purified using in ice water. Gels were analyzed by Phosphor-Imaging on a Storm
anion-exchange chromatography. Cleavage assays were carried out 860 (Molecular Dynamics), using ImageQuaNT software. SigmaPlot
at 25C in buffer containing 20 mM Tris-HCl (pH 7.3), 150 mM NaCl, 8.0 (SPSS) was used for statistical analysis and graph plotting. Ex-
1% dimethyl sulphoxide (DMSO), with or without inhibitors. 200 nM periments were carried out in triplicate and repeated twice. Results
purified SARS-CoV Mpro was preincubated with the buffer for 30 min are expressed as a percentage of controls in the absence of inhibi-
at 25C, and a synthetic substrate H2N-TSAVLQSGFRKW-COOH tors. The mean value is shown with SD. Dose-response data are
(SynPep) was added to a final concentration of 500 M to initiate best fit to the logistic equation.
the reaction. The cleavage products were resolved by HPLC using
a SOURCE 5RPC column (2.1  150 mm) (Amersham Biosciences) Pseudotype Virus Entry Assay
with a 20 min linear gradient of 10%–30% acetonitrile in 0.1% trifluo- SARS-CoV full-length S protein was used to pseudotype HIV-1 back-
roacetic acid (TFA). The absorbance was determined at 215 or 280 bone carrying a luciferase reporter gene. The pseudotype virus was
nm, and peak areas were integrated to quantify the cleavage prod- generated by cotransfecting 293T cells with an optimized S gene
ucts. The initial rates of cleavage were determined under the condi- expression plasmid and a vector carrying HIV-1NL4-3Luc	 genome
tion that 5%–10% of the total substrate was cleaved. SigmaPlot 8.0 (L.Z. and D.D.H., unpublished data). The pseudotype virus was sub-
(SPSS) was used for statistical analysis and graph plotting. Experi- sequently used to infect 293T ACE2 cells. When the inhibition assay
ments were carried out in triplicate and repeated twice. Results are was performed, the pseudotype virus was first incubated with the
expressed as a percentage of controls in the absence of inhibitors. inhibitors for 30 min at 37C before addition to the target cells. The
The mean value is shown with SD. Dose-response data are best fit infected cells were cultured for an additional 72 hr before measure-
to the logistic equation. ment of luciferase activity. SigmaPlot 8.0 (SPSS) was used for statis-
tical analysis and graph plotting. Experiments were carried out in
Molecular Docking triplicate and repeated twice. Results are expressed as a percentage
The atomic coordinates of SARS-CoV Mpro were downloaded from of controls in the absence of inhibitors. The mean value is shown
Protein Data bank (PDB ID code 1UK4). The three-dimensional struc- with SD. Dose-response data are best fit to the logistic equation.
ture of compound MP576 was generated by Chem3D (Cam-
bridgeSoft). Hydrogen atoms were assigned using InsightII (Accel-
Acknowledgmentsrys), and partial charge and potential were assigned by CHARMM
force field. Autodock3.0.5 Lamarckian Genetic Algorithm [26] and
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